The European Medicines Agency (EMA) is set to enhance transparency and support for stakeholders by hosting a series of monthly Q&A clinics focused on the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service. Scheduled to commence on October 14, 2025, these online sessions aim to address queries and facilitate better understanding of regulatory data management.
Comprehensive Support for Regulatory Data Management
EMA’s regulatory data management services team will lead the Q&A sessions, providing expert insights into the XEVMPD service. These clinics are designed to assist pharmaceutical companies, healthcare professionals, and other stakeholders in navigating the complexities of medicinal product data management. By offering direct access to EMA experts, the sessions aim to streamline the submission and monitoring processes within the regulatory framework.
Accessible Learning Opportunities Through Live Broadcasts
Conducted online, the Q&A clinics ensure wide accessibility for participants across Europe and beyond. Each session will be live-streamed, allowing real-time interaction between attendees and EMA officials. Additionally, recordings of the sessions will be available post-event, providing ongoing reference material for those unable to attend the live broadcast.
– Enhanced understanding of XEVMPD functionalities
– Improved compliance with EMA regulatory requirements
– Strengthened collaboration between EMA and industry stakeholders
These inferences suggest that the Q&A sessions will not only demystify the XEVMPD service but also foster a more collaborative environment between the EMA and the pharmaceutical sector. Participants are likely to gain actionable knowledge that can lead to more efficient regulatory submissions and better post-marketing surveillance of medicinal products.
Engaging regularly through monthly clinics until the end of 2025, the EMA demonstrates its commitment to ongoing support and education in the realm of medicinal product regulation. By addressing common challenges and offering solutions in a structured format, the agency aims to bolster the overall quality and safety of medicinal products within the European market.
Additionally, dedicated Q&A clinics for Substance, Organisation, and Referential Management Services will run concurrently, ensuring comprehensive coverage of all aspects related to the SPOR master data. This targeted approach allows stakeholders to seek specific guidance tailored to their unique operational needs.
Participants interested in these sessions can register through the EMA’s official channels. The proactive initiative underscores EMA’s role in facilitating clear and effective communication, ultimately contributing to the advancement of public health standards across Europe.
Staying informed about these opportunities enables stakeholders to leverage EMA’s resources effectively, ensuring compliance and enhancing the quality of medicinal product data management practices. Engaging with these Q&A clinics represents a strategic step towards more robust regulatory processes and improved healthcare outcomes.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
